482 related articles for article (PubMed ID: 35241494)
21. The current management and biomarkers of immunotherapy in advanced gastric cancer.
Chang X; Ge X; Zhang Y; Xue X
Medicine (Baltimore); 2022 May; 101(21):e29304. PubMed ID: 35623069
[TBL] [Abstract][Full Text] [Related]
22. Distribution of the Epstein-Barr virus in the normal stomach and gastric lesions in Thai population.
Wanvimonsuk S; Thitiwanichpiwong P; Keelawat S; Mutirangura A; Kitkumthorn N
J Med Virol; 2019 Mar; 91(3):444-449. PubMed ID: 30229949
[TBL] [Abstract][Full Text] [Related]
23. The tumor immune composition of mismatch repair deficient and Epstein-Barr virus-positive gastric cancer: A systematic review.
Bos J; Groen-van Schooten TS; Brugman CP; Jamaludin FS; van Laarhoven HWM; Derks S
Cancer Treat Rev; 2024 Jun; 127():102737. PubMed ID: 38669788
[TBL] [Abstract][Full Text] [Related]
24. [Clinicopathological and molecular characteristics of Epstein-Barr virus associated gastric cancer: a single center large sample case investigation].
Yang Y; Liu YQ; Wang XH; Ji K; Li ZW; Bai J; Yang AR; Hu Y; Han HB; Li ZY; Bu ZD; Wu XJ; Zhang LH; Ji JF
Beijing Da Xue Xue Bao Yi Xue Ban; 2019 Jun; 51(3):451-458. PubMed ID: 31209416
[TBL] [Abstract][Full Text] [Related]
25. Tumor Mutational Burden Determined by Panel Sequencing Predicts Survival After Immunotherapy in Patients With Advanced Gastric Cancer.
Kim J; Kim B; Kang SY; Heo YJ; Park SH; Kim ST; Kang WK; Lee J; Kim KM
Front Oncol; 2020; 10():314. PubMed ID: 32232003
[No Abstract] [Full Text] [Related]
26. Prevalence and characteristics of Epstein-Barr virus associated gastric carcinoma in Gansu Province, Northwest China with mRNA expression of glycoprotein BMRF2.
Guo C; Wei J; Scott RS; Chen Y; Chen Z; Zhao W; Zhang C; Wang B; Chai C; Dai G; Li M; Zhang F
J Med Virol; 2020 Mar; 92(3):356-363. PubMed ID: 31663617
[TBL] [Abstract][Full Text] [Related]
27. Epstein-Barr virus and mismatch repair deficiency status differ between oesophageal and gastric cancer: A large multi-centre study.
Hewitt LC; Inam IZ; Saito Y; Yoshikawa T; Quaas A; Hoelscher A; Bollschweiler E; Fazzi GE; Melotte V; Langley RE; Nankivell M; Cunningham D; Allum W; Hutchins GG; Grabsch HI
Eur J Cancer; 2018 May; 94():104-114. PubMed ID: 29550565
[TBL] [Abstract][Full Text] [Related]
28. Clinicopathological features of programmed death ligand 1 expression with tumor-infiltrating lymphocyte, mismatch repair, and Epstein-Barr virus status in a large cohort of gastric cancer patients.
Kawazoe A; Kuwata T; Kuboki Y; Shitara K; Nagatsuma AK; Aizawa M; Yoshino T; Doi T; Ohtsu A; Ochiai A
Gastric Cancer; 2017 May; 20(3):407-415. PubMed ID: 27629881
[TBL] [Abstract][Full Text] [Related]
29. Clinicopathological and prognostic features of Epstein-Barr virus infection, microsatellite instability, and PD-L1 expression in gastric cancer.
Pereira MA; Ramos MFKP; Faraj SF; Dias AR; Yagi OK; Zilberstein B; Cecconello I; Alves VAF; de Mello ES; Ribeiro U
J Surg Oncol; 2018 Apr; 117(5):829-839. PubMed ID: 29534305
[TBL] [Abstract][Full Text] [Related]
30. The immune microenvironment features and response to immunotherapy in EBV-associated lymphoepithelioma-like cholangiocarcinoma.
Chiang NJ; Hou YC; Tan KT; Tsai HW; Lin YJ; Yeh YC; Chen LT; Hou YF; Chen MH; Shan YS
Hepatol Int; 2022 Oct; 16(5):1137-1149. PubMed ID: 35780451
[TBL] [Abstract][Full Text] [Related]
31. Loss of viral genome with altered immune microenvironment during tumour progression of Epstein-Barr virus-associated gastric carcinoma.
Kondo A; Shinozaki-Ushiku A; Rokutan H; Kunita A; Ikemura M; Yamashita H; Seto Y; Nagae G; Tatsuno K; Aburatani H; Koinuma D; Ushiku T
J Pathol; 2023 Jun; 260(2):124-136. PubMed ID: 36806225
[TBL] [Abstract][Full Text] [Related]
32. Case report: Long response to PD-1 blockade after failure of trastuzumab plus chemotherapy in advanced Epstein-Barr virus-associated gastric cancer.
Pan Y; Lu L; Liu H; Chen D; Han N; Yao R; Wang X; Gao X; Yu J; Chen L; Zhou F; Hao G; Lu Y; Li M; He G; Kang F; Li Z; Tang Y; Zhang J; Wei L; Nie Y
Front Immunol; 2022; 13():1003859. PubMed ID: 36353623
[TBL] [Abstract][Full Text] [Related]
33. Gastritis-Infection-Cancer Sequence of Epstein-Barr Virus-Associated Gastric Cancer.
Fukayama M; Kunita A; Kaneda A
Adv Exp Med Biol; 2018; 1045():437-457. PubMed ID: 29896679
[TBL] [Abstract][Full Text] [Related]
34.
Klümper N; Ralser DJ; Zarbl R; Schlack K; Schrader AJ; Rehlinghaus M; Hoffmann MJ; Niegisch G; Uhlig A; Trojan L; Steinestel J; Steinestel K; Wirtz RM; Sikic D; Eckstein M; Kristiansen G; Toma M; Hölzel M; Ritter M; Strieth S; Ellinger J; Dietrich D
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34446578
[TBL] [Abstract][Full Text] [Related]
35. Clinicopathologic Characteristics of Epstein-Barr Virus-Associated Gastric Cancer Over the Past Decade in Japan.
Yanagi A; Nishikawa J; Shimokuri K; Shuto T; Takagi T; Takagi F; Kobayashi Y; Yamamoto M; Miura O; Yanai H; Suehiro Y; Yamasaki T; Yoshiyama H; Sakaida I
Microorganisms; 2019 Sep; 7(9):. PubMed ID: 31480554
[No Abstract] [Full Text] [Related]
36. Prospective observation: Clinical utility of plasma Epstein-Barr virus DNA load in EBV-associated gastric carcinoma patients.
Qiu MZ; He CY; Lu SX; Guan WL; Wang F; Wang XJ; Jin Y; Wang FH; Li YH; Shao JY; Zhou ZW; Yun JP; Xu RH
Int J Cancer; 2020 Jan; 146(1):272-280. PubMed ID: 31162842
[TBL] [Abstract][Full Text] [Related]
37. Clinical significance of spasmolytic polypeptide-expressing metaplasia and intestinal metaplasia in Epstein-Barr virus-associated and Epstein-Barr virus-negative gastric cancer.
Zhang Y; Chen JN; Dong M; Zhang ZG; Zhang YW; Wu JY; Du H; Li HG; Huang Y; Shao CK
Hum Pathol; 2017 May; 63():128-138. PubMed ID: 28300576
[TBL] [Abstract][Full Text] [Related]
38. Viral loads correlate with upregulation of PD-L1 and worse patient prognosis in Epstein-Barr Virus-associated gastric carcinoma.
Nakayama A; Abe H; Kunita A; Saito R; Kanda T; Yamashita H; Seto Y; Ishikawa S; Fukayama M
PLoS One; 2019; 14(1):e0211358. PubMed ID: 30695048
[TBL] [Abstract][Full Text] [Related]
39. Epstein-Barr virus-encoded miR-BART5-5p upregulates PD-L1 through PIAS3/pSTAT3 modulation, worsening clinical outcomes of PD-L1-positive gastric carcinomas.
Yoon CJ; Chang MS; Kim DH; Kim W; Koo BK; Yun SC; Kim SH; Kim YS; Woo JH
Gastric Cancer; 2020 Sep; 23(5):780-795. PubMed ID: 32206940
[TBL] [Abstract][Full Text] [Related]
40. Epstein-Barr virus-associated gastric cancer: A distinct subtype.
Yang J; Liu Z; Zeng B; Hu G; Gan R
Cancer Lett; 2020 Dec; 495():191-199. PubMed ID: 32979463
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
